FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.

IF 4.6 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2026-09-14 eCollection Date: 2026-01-01 DOI:10.32604/or.2026.084987
Zhen Li, Xinya Yu, Boning Wu, Jialin Zhang, Xinyu Ju, Yajun Wang, Jieli Song, Qiao Liu, Peng Huang, Qi Ding, Yupeng Wu
{"title":"FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.","authors":"Zhen Li, Xinya Yu, Boning Wu, Jialin Zhang, Xinyu Ju, Yajun Wang, Jieli Song, Qiao Liu, Peng Huang, Qi Ding, Yupeng Wu","doi":"10.32604/or.2026.084987","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Fascin actin-bundling protein 1 (<i>FSCN1</i>) modulates the expression of key lipogenic enzymes fatty acid synthase (<i>FASN</i>) and stearoyl-CoA desaturase (<i>SCD1</i>) in colorectal cancer (CRC), but the underlying mechanisms remain elusive. <b>Methods:</b> Bioinformatics analyses were performed to evaluate FSCN1 expression and its prognostic value in CRC. Intracellular lipid levels following <i>FSCN1</i> knockdown were assessed by Nile Red/DAPI co-staining and triglyceride quantification, and further validated by Oil Red O staining of xenograft tumors. Expression levels of key metabolic enzymes were measured by qRT-PCR and Western blotting. RNA sequencing identified FSCN1-associated pathways, which were functionally investigated using pharmacological inhibitors. <b>Results:</b> FSCN1 was significantly upregulated in CRC (<i>p</i> < 0.001; AUC = 0.796) and was correlated with poorer overall survival (<i>p</i> = 0.018). FSCN1 depletion reduced intracellular lipid accumulation, accompanied by downregulation of lipogenic mediators-sterol regulatory element-binding transcription factor 1 (<i>SREBF1</i>; protein product: SREBP1), FASN, and SCD1-and upregulation of peroxisomal fatty acid oxidation (FAO)-related factors-peroxisome proliferator-activated receptor alpha (<i>PPARA</i>; protein product: PPARα) and acyl-CoA oxidase 1 (<i>ACOX1</i>). Mechanistically, FSCN1 was associated with activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) and p38 mitogen-activated protein kinase (p38 MAPK) pathways; pharmacological inhibition with LY294002 or SB203580 phenocopied the lipid-lowering effects of <i>FSCN1</i> knockdown. <b>Conclusion:</b> Collectively, these findings link FSCN1 to the AKT/mTOR/SREBP1/(FASN/SCD1) lipogenic axis and the p38 MAPK/PPARα/ACOX1 peroxisomal FAO pathway, implicating FSCN1 in lipid metabolic regulation and CRC progression, while suggesting a putative functional regulatory axis and a promising candidate therapeutic target for CRC.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"34 10","pages":"24"},"PeriodicalIF":4.6000,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591365/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2026.084987","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fascin actin-bundling protein 1 (FSCN1) modulates the expression of key lipogenic enzymes fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD1) in colorectal cancer (CRC), but the underlying mechanisms remain elusive. Methods: Bioinformatics analyses were performed to evaluate FSCN1 expression and its prognostic value in CRC. Intracellular lipid levels following FSCN1 knockdown were assessed by Nile Red/DAPI co-staining and triglyceride quantification, and further validated by Oil Red O staining of xenograft tumors. Expression levels of key metabolic enzymes were measured by qRT-PCR and Western blotting. RNA sequencing identified FSCN1-associated pathways, which were functionally investigated using pharmacological inhibitors. Results: FSCN1 was significantly upregulated in CRC (p < 0.001; AUC = 0.796) and was correlated with poorer overall survival (p = 0.018). FSCN1 depletion reduced intracellular lipid accumulation, accompanied by downregulation of lipogenic mediators-sterol regulatory element-binding transcription factor 1 (SREBF1; protein product: SREBP1), FASN, and SCD1-and upregulation of peroxisomal fatty acid oxidation (FAO)-related factors-peroxisome proliferator-activated receptor alpha (PPARA; protein product: PPARα) and acyl-CoA oxidase 1 (ACOX1). Mechanistically, FSCN1 was associated with activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) and p38 mitogen-activated protein kinase (p38 MAPK) pathways; pharmacological inhibition with LY294002 or SB203580 phenocopied the lipid-lowering effects of FSCN1 knockdown. Conclusion: Collectively, these findings link FSCN1 to the AKT/mTOR/SREBP1/(FASN/SCD1) lipogenic axis and the p38 MAPK/PPARα/ACOX1 peroxisomal FAO pathway, implicating FSCN1 in lipid metabolic regulation and CRC progression, while suggesting a putative functional regulatory axis and a promising candidate therapeutic target for CRC.

FSCN1调节结直肠癌细胞中脂肪酸代谢和AKT/mTOR和p38 MAPK通路的协同激活
背景:结直肠癌(CRC)中,束蛋白肌动蛋白捆绑蛋白1 (FSCN1)调节关键脂肪生成酶脂肪酸合成酶(FASN)和硬脂酰辅酶a去饱和酶(SCD1)的表达,但其潜在机制尚不清楚。方法:采用生物信息学方法评价FSCN1在结直肠癌中的表达及其预后价值。通过尼罗红/DAPI共染色和甘油三酯定量评估FSCN1敲除后的细胞内脂质水平,并通过异种移植肿瘤的油红O染色进一步验证。采用qRT-PCR和Western blotting检测关键代谢酶的表达水平。RNA测序鉴定了fscn1相关通路,并使用药理学抑制剂对其进行了功能研究。结果:FSCN1在CRC中显著上调(p < 0.001; AUC = 0.796),并与较差的总生存率相关(p = 0.018)。FSCN1耗散降低了细胞内脂质积累,并伴有脂质生成介质-甾醇调节元件结合转录因子1 (SREBF1,蛋白产物:SREBP1)、FASN和scd1 -的下调,以及过氧化物酶体脂肪酸氧化(FAO)相关因子-过氧化物酶体增殖因子激活受体α (PPARA,蛋白产物:PPARα)和酰基辅酶a氧化酶1 (ACOX1)的上调。机制上,FSCN1与蛋白激酶B/哺乳动物雷帕霉素靶蛋白(AKT/mTOR)和p38丝裂原活化蛋白激酶(p38 MAPK)通路的激活有关;LY294002或SB203580对FSCN1敲低的降脂作用进行了表型抑制。结论:总的来说,这些发现将FSCN1与AKT/mTOR/SREBP1/(FASN/SCD1)脂质生成轴和p38 MAPK/PPARα/ACOX1过氧化酶体FAO通路联系起来,暗示FSCN1参与脂质代谢调节和CRC进展,同时提出了一个假设的功能调节轴和一个有希望的CRC候选治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书